Entering text into the input field will update the search result below

Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead


  • Day One Biopharmaceuticals declared strong data in relapsed glioma in June.
  • The company has strong cash position.
  • They may submit an NDA next year.
  • Looking for more investing ideas like this one? Get them exclusively at The Total Pharma Tracker. Learn More »

Glioma - brain tumor


Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is a developer of targeted cancer therapies for a variety of tumors, with a lead candidate targeting brain cancers called glioma. Lead drug, Tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, is in a pivotal

About the TPT service

Thanks for reading. At the Total Pharma Tracker, we offer the following:-

Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. 

For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.

Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you. 

This article was written by

Avisol Capital Partners profile picture

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in DAWN over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (1)

NDHT profile picture
Thanks for introducing this "new" company to me.

Based on DAWN, the first patient was dosed in May 2021. Registrational pLGG arm completed enrollment in May 2022. The protocol for the treatment period is: minimum of 2 years or until progression or toxicity/intolerability.

So the positive data they reported back in June is based on a little bit over one third of the total patients (n=60), or 22. In addition, one has to assume that none of these patients have been treated for over two years. Even when they report the topline results in the 1Q 2023, I doubt that any of the patients would reach the minimum two years on treatment, which sounds like a violation of their protocol, unless all the patients have either progressed or have severe toxicity, which is not good.

Immature and incomplete data means that there shall be better entry points, if one wants it.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.